Agenus (FRA:AJ8) Construction In Progress : €0.0 Mil (As of Mar. 2024)

View and export this data going back to . Start your Free Trial

What is Agenus Construction In Progress?

Agenus's quarterly construction in progress increased from Sep. 2023 (€0.0 Mil) to Dec. 2023 (€1.4 Mil) but then declined from Dec. 2023 (€1.4 Mil) to Mar. 2024 (€0.0 Mil).

Agenus's annual construction in progress increased from Dec. 2021 (€14.9 Mil) to Dec. 2022 (€62.7 Mil) but then declined from Dec. 2022 (€62.7 Mil) to Dec. 2023 (€1.4 Mil).

Agenus Construction In Progress Historical Data

The historical data trend for Agenus's Construction In Progress can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Agenus Construction In Progress Chart

Agenus Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Construction In Progress

Get a 7-Day Free Trial

14.90

62.74

1.39

Agenus Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Construction In Progress	Get a 7-Day Free Trial															-	-	-	1.39	-

Agenus Construction In Progress Calculation

It records the cost of construction work, which is not yet completed (typically, applied to capital budget items). A construction in progress item is not depreciated until the asset is placed in service. Normally, upon completion, a construction in progress item is reclassified, and the reclassified asset is capitalized and depreciated.

Agenus (FRA:AJ8) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Agenus Inc (FRA:AJ8) » Definitions » Construction In Progress

Comparable Companies

Traded in Other Exchanges

AGEN:USA AJ81:Germany

Address

3 Forbes Road, Lexington, MA, USA, 02421

Website

https://www.agenusbio.com

Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).

Agenus (FRA:AJ8) Headlines

No Headlines